Could six months of therapy be enough for some breast cancer patients?

This study looks at whether women with early-stage HER2-positive breast cancer who have a complete response to initial chemotherapy and HER2-targeted therapy can safely receive only 6 months of further HER2-targeted treatment instead of the usual 12 months. The goal is to reduce side effects, treatment burden, and costs while maintaining good outcomes. About 52 participants across multiple Canadian centers will be enrolled to see if this shorter approach is feasible and safe.